NZ629122A - Liver x receptor modulators - Google Patents
Liver x receptor modulatorsInfo
- Publication number
- NZ629122A NZ629122A NZ629122A NZ62912213A NZ629122A NZ 629122 A NZ629122 A NZ 629122A NZ 629122 A NZ629122 A NZ 629122A NZ 62912213 A NZ62912213 A NZ 62912213A NZ 629122 A NZ629122 A NZ 629122A
- Authority
- NZ
- New Zealand
- Prior art keywords
- liver
- compounds
- receptor modulators
- imidazo
- compositions
- Prior art date
Links
- 102000004311 liver X receptors Human genes 0.000 title abstract 3
- 108090000865 liver X receptors Proteins 0.000 title abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- CVGPZQMGLKRVJV-UHFFFAOYSA-N 1,2,3,4-tetrahydropyrazino[1,2-a]benzimidazole Chemical class C1=CC=C2N3CCNCC3=NC2=C1 CVGPZQMGLKRVJV-UHFFFAOYSA-N 0.000 abstract 1
- AEIDURNZWCNQIM-UHFFFAOYSA-N 1,2,3,4-tetrahydropyrazino[1,2-a]indole Chemical class C1=CC=C2N3CCNCC3=CC2=C1 AEIDURNZWCNQIM-UHFFFAOYSA-N 0.000 abstract 1
- CABUZECPUSGGRX-QGZVFWFLSA-N [(1r)-7-methylsulfonyl-1-propan-2-yl-2-[4-(trifluoromethyl)pyrimidin-2-yl]-3,4-dihydro-1h-pyrazino[1,2-a]benzimidazol-8-yl]methanol Chemical compound N1([C@@H](C=2N(C3=CC(=C(CO)C=C3N=2)S(C)(=O)=O)CC1)C(C)C)C1=NC=CC(C(F)(F)F)=N1 CABUZECPUSGGRX-QGZVFWFLSA-N 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 125000000714 pyrimidinyl group Chemical group 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Psychology (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Ophthalmology & Optometry (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Vascular Medicine (AREA)
- Transplantation (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261612051P | 2012-03-16 | 2012-03-16 | |
| PCT/US2013/031242 WO2013138565A1 (en) | 2012-03-16 | 2013-03-14 | Liver x receptor modulators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ629122A true NZ629122A (en) | 2016-04-29 |
Family
ID=47997957
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ629122A NZ629122A (en) | 2012-03-16 | 2013-03-14 | Liver x receptor modulators |
Country Status (27)
| Country | Link |
|---|---|
| US (4) | US9006244B2 (enExample) |
| EP (1) | EP2825541B1 (enExample) |
| JP (3) | JP6114814B2 (enExample) |
| KR (1) | KR102069912B1 (enExample) |
| CN (1) | CN104203951B (enExample) |
| AU (1) | AU2013232066B2 (enExample) |
| CA (1) | CA2866218C (enExample) |
| CY (1) | CY1118318T1 (enExample) |
| DK (1) | DK2825541T3 (enExample) |
| EA (1) | EA026907B1 (enExample) |
| ES (1) | ES2598653T3 (enExample) |
| HR (1) | HRP20161196T1 (enExample) |
| HU (1) | HUE029402T2 (enExample) |
| IL (1) | IL234265B (enExample) |
| IN (1) | IN2014DN07636A (enExample) |
| LT (1) | LT2825541T (enExample) |
| ME (1) | ME02534B (enExample) |
| MX (1) | MX354818B (enExample) |
| NZ (1) | NZ629122A (enExample) |
| PL (1) | PL2825541T3 (enExample) |
| PT (1) | PT2825541T (enExample) |
| RS (1) | RS55166B1 (enExample) |
| SG (1) | SG11201405328SA (enExample) |
| SI (1) | SI2825541T1 (enExample) |
| SM (1) | SMT201600374B (enExample) |
| WO (1) | WO2013138565A1 (enExample) |
| ZA (1) | ZA201406326B (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013138568A1 (en) | 2012-03-16 | 2013-09-19 | Vitae Pharmaceuticals, Inc. | Liver x reception modulators |
| WO2013138565A1 (en) * | 2012-03-16 | 2013-09-19 | Vitae Pharmaceuticals, Inc. | Liver x receptor modulators |
| EP3091970B1 (en) | 2014-01-10 | 2020-10-28 | Rgenix, Inc. | Lxr agonists and uses thereof |
| WO2015195922A1 (en) * | 2014-06-19 | 2015-12-23 | Vitae Pharmaceuticals, Inc. | Compounds for use in treating acute coronary syndrome and related conditions |
| JP6605583B2 (ja) * | 2014-08-07 | 2019-11-13 | ヴァイティー ファーマシューティカルズ，エルエルシー | 肝臓ｘ受容体モジュレーターとしてのピペラジン誘導体 |
| WO2016100619A2 (en) * | 2014-12-17 | 2016-06-23 | Rgenix, Inc. | Treatment and diagnosis of cancer |
| CN105017262B (zh) * | 2015-07-07 | 2017-05-03 | 广东也乐新材料制造有限公司 | 一种醛基取代多环杂芳烃化合物的合成方法 |
| CN105288658B (zh) * | 2015-10-30 | 2018-08-28 | 中国人民解放军第三军医大学 | miR-18a-5p抑制剂在制备防治骨质疏松药物中的应用 |
| JP7025022B2 (ja) | 2016-01-11 | 2022-02-24 | ザ ロックフェラー ユニバーシティー | 骨髄系由来抑制細胞関連障害の治療のための方法 |
| EP3713575A4 (en) | 2017-11-21 | 2021-08-25 | Rgenix, Inc. | POLYMORPHS AND THEIR USES |
| PL4073025T3 (pl) | 2019-12-13 | 2024-09-16 | Inspirna, Inc. | Sole metali i ich zastosowania |
Family Cites Families (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4748247A (en) | 1986-10-21 | 1988-05-31 | American Home Products Corporation | 2-[4-[4-(2-Pyrimidinyl)-1-piperazinyl]alkyl]alkyl]pyrido- and pyrazino-indole-1,3-dione derivatives as histamine H1 antagonists |
| JPH05503518A (ja) | 1990-01-22 | 1993-06-10 | イー・アイ・デユポン・ドウ・ヌムール・アンド・カンパニー | 除草性スルホニル尿素 |
| EP0572863A1 (de) | 1992-06-05 | 1993-12-08 | F. Hoffmann-La Roche Ag | ZNS Pyrazinoindole |
| US5545636A (en) | 1993-12-23 | 1996-08-13 | Eli Lilly And Company | Protein kinase C inhibitors |
| WO1995017182A1 (en) | 1993-12-23 | 1995-06-29 | Eli Lilly And Company | Protein kinase c inhibitors |
| AU3831495A (en) | 1994-10-20 | 1996-05-15 | American Home Products Corporation | Indole derivatives useful as serotonergic agents |
| CA2258093A1 (en) | 1996-06-28 | 1998-01-08 | Mark E. Duggan | Fibrinogen receptor antagonists |
| CA2257937A1 (en) | 1996-06-28 | 1998-01-08 | Merck & Co., Inc. | Fibrinogen receptor antagonist prodrugs |
| US5854245A (en) | 1996-06-28 | 1998-12-29 | Merck & Co., Inc. | Fibrinogen receptor antagonists |
| WO1998000401A1 (en) | 1996-06-28 | 1998-01-08 | Merck & Co., Inc. | Fibrinogen receptor antagonist prodrugs |
| US6177440B1 (en) | 1996-10-30 | 2001-01-23 | Eli Lilly And Company | Substituted tricyclics |
| FR2761073B1 (fr) | 1997-03-20 | 1999-04-23 | Synthelabo | Derives de pyrazino[1,2-a]indole-1-one, leur preparation et leur application en therapeutique |
| FR2761070B1 (fr) | 1997-03-20 | 1999-04-23 | Synthelabo | Derives de dihydropyrazino[1,2-a]indole-1-one, leur preparation et leur application en therapeutique |
| DE19802235A1 (de) | 1998-01-22 | 1999-07-29 | Bayer Ag | Mit tricyclischen Indolen substituierte Oxazolidinone |
| IL129484A0 (en) | 1998-04-17 | 2000-02-29 | Lilly Co Eli | Substituted tricyclics |
| JP2002544197A (ja) | 1999-05-06 | 2002-12-24 | ニューロゲン コーポレイション | 置換４−オキソ−キノリン−３−カルボキサミド：ｇａｂａ脳受容体リガンド |
| US7037916B2 (en) | 1999-07-15 | 2006-05-02 | Pharmacopeia Drug Discovery, Inc. | Pyrimidine derivatives as IL-8 receptor antagonists |
| IT1313593B1 (it) | 1999-08-03 | 2002-09-09 | Novuspharma Spa | Derivati di 1,2-diidro-1-oxo-pirazino 1,2-a indolo. |
| AU1189201A (en) | 1999-10-22 | 2001-05-08 | Eli Lilly And Company | Therapeutic compositions including protein kinase c inhibitors |
| CA2396257A1 (en) | 2000-01-06 | 2001-07-12 | Merck Frosst Canada & Co./Merck Frosst Canada & Cie | Novel compounds and compositions as protease inhibitors |
| CN1277828C (zh) | 2000-07-31 | 2006-10-04 | 霍夫曼-拉罗奇有限公司 | 哌嗪衍生物 |
| JP2005506280A (ja) | 2000-12-20 | 2005-03-03 | ブリストル−マイヤーズ・スクイブ・ファーマ・カンパニー | アリールおよびアミノアリール置換セロトニン受容体アゴニストおよびアンタゴニストリガンド |
| GB0106177D0 (en) | 2001-03-13 | 2001-05-02 | Hoffmann La Roche | Piperazine derivatives |
| FR2829766A1 (fr) | 2001-09-14 | 2003-03-21 | Lipha | Derives d'oxamates comportant un heterocycle azote diversement substitue |
| CN1617725A (zh) | 2001-12-21 | 2005-05-18 | 王者制药研究发展有限公司 | 酪氨酰衍生物及其作为p2x7受体调节剂的用途 |
| US7919497B2 (en) | 2002-08-02 | 2011-04-05 | Nereus Pharmaceuticals, Inc. | Analogs of dehydrophenylahistins and their therapeutic use |
| DE10320780A1 (de) | 2003-05-09 | 2005-01-20 | Bayer Healthcare Ag | Heterocyclyl-substituierte Dihydrochinazoline |
| EP1714961B1 (en) | 2004-02-12 | 2015-12-09 | Mitsubishi Tanabe Pharma Corporation | Indazole compound and pharmaceutical use thereof |
| BRPI0509754A (pt) | 2004-04-08 | 2007-10-16 | Novartis Ag | inibidores de proteìna quinase c para o tratamento de doenças auto-imunes e de rejeição a transplante |
| RU2266906C1 (ru) | 2004-04-29 | 2005-12-27 | Общество с ограниченной ответственностью "Исследовательский Институт Химического Разнообразия" (ООО "Исследовательский Институт Химического Разнообразия") | Анелированные карбамоилазагетероциклы, способы их получения (варианты), фармацевтическая композиция, фокусированная библиотека |
| ITMI20040874A1 (it) | 2004-04-30 | 2004-07-30 | Ist Naz Stud Cura Dei Tumori | Derivati indolici ed azaindolici con azione antitumorale |
| WO2005113526A2 (en) | 2004-05-21 | 2005-12-01 | Pfizer Products Inc. | Metabolites of 4-(3,4-dichloro-phenyl)-2-[2-(4-methyl-piperazin-1-yl)-benzylidene]-thiomorpholin-3-one |
| MX2007006896A (es) | 2004-12-15 | 2007-06-26 | Hoffmann La Roche | Fenil-metanonas bi- y triciclicas sustituidas como inhibidores del transportador 1 de glicina (glyt-1) para el tratamiento de la enfermedad de alzheimer. |
| WO2006072608A2 (en) | 2005-01-03 | 2006-07-13 | Universitá Degli Studi Di Siena | Aryl piperazine derivatives for the treatment of neuropsychiatric disorders |
| US7790712B2 (en) | 2005-03-17 | 2010-09-07 | Boehringer Ingelheim Pharmaceutical, Inc. | Substituted [1,4]diazepino[1,2-A]indoles and azepino[1,2-A]indoles as anti-cytokine inhibitors |
| WO2006106423A2 (en) | 2005-04-07 | 2006-10-12 | Pfizer Inc. | Amino sulfonyl derivatives as inhibitors of human 11-.beta.-hydrosysteroid dehydrogenase |
| ES2317558T3 (es) | 2005-07-14 | 2009-04-16 | F. Hoffmann-La Roche Ag | Derivados de indol-3-il-espiro-piperidina como antagonistas del receptr v1a. |
| WO2007035841A1 (en) | 2005-09-21 | 2007-03-29 | Nereus Pharmaceuticals, Inc. | Analogs of dehydrophenylahistins and their therapeutic use |
| EP1779848A1 (en) | 2005-10-28 | 2007-05-02 | Nikem Research S.R.L. | V-ATPase inhibitors for the treatment of inflammatory and autoimmune diseases |
| JP2007137810A (ja) | 2005-11-17 | 2007-06-07 | Sankyo Co Ltd | インドール化合物を含有する医薬 |
| DE602006010433D1 (de) | 2005-12-09 | 2009-12-24 | Hoffmann La Roche | Für die behandlung von obesitas geeignete tricyclische amidderivate |
| US7351706B2 (en) | 2006-01-05 | 2008-04-01 | Hoffmann-La Roche Inc. | Indol-3-yl-carbonyl-spiro-piperidine derivatives |
| FR2897061B1 (fr) | 2006-02-03 | 2010-09-03 | Sanofi Aventis | Derives de n-heteroaryl-carboxamides tricycliques contenant un motif benzimidazole, leur preparation et leur application en therapeutique. |
| RU2318818C1 (ru) | 2006-04-12 | 2008-03-10 | Общество С Ограниченной Ответственностью "Исследовательский Институт Химического Разнообразия" | Азагетероциклы, комбинаторная библиотека, фокусированная библиотека, фармацевтическая композиция и способ получения (варианты) |
| US8129527B2 (en) | 2006-11-03 | 2012-03-06 | Nereus Pharmacuticals, Inc. | Analogs of dehydrophenylahistins and their therapeutic use |
| CN101679220A (zh) | 2007-04-09 | 2010-03-24 | 梅特希尔基因公司 | 组蛋白脱乙酰酶抑制剂 |
| WO2009003003A2 (en) | 2007-06-25 | 2008-12-31 | Neurogen Corporation | Piperazinyl oxoalkyl tetrahydro-beta-carbolines and related analogues |
| WO2009042092A1 (en) | 2007-09-25 | 2009-04-02 | Merck & Co., Inc. | 2-aryl or heteroaryl indole derivatives |
| CN101456863B (zh) | 2007-12-14 | 2012-04-25 | 华北制药集团新药研究开发有限责任公司 | Lxr激动剂及其制备方法和用途 |
| BRPI0822239A2 (pt) * | 2007-12-21 | 2015-06-30 | Wyeth Llc | Composto de pirazolo[1,5-a] pirimidina |
| KR20100130596A (ko) | 2008-01-22 | 2010-12-13 | 다케다 야쿠힌 고교 가부시키가이샤 | 부신 피질 자극 호르몬 방출 인자 길항 작용을 갖는 3 환식 화합물 및 이를 함유하는 약학 조성물 |
| US20090192147A1 (en) | 2008-01-30 | 2009-07-30 | Wyeth | [a]-FUSED INDOLE COMPOUNDS, THEIR USE AS mTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES |
| US20100137320A1 (en) | 2008-02-29 | 2010-06-03 | Schering Corporation | Gamma secretase modulators |
| US8207165B2 (en) | 2008-03-28 | 2012-06-26 | Nerviano Medical Sciences S.R.L. | 3,4-dihydro-2H-pyrazino[1,2-A]indol-1-one derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them |
| TW201031665A (en) | 2009-02-04 | 2010-09-01 | Gruenenthal Gmbh | Substituted indole-compound |
| CA2764622A1 (en) | 2009-06-08 | 2010-12-16 | Stefan Schunk | Substituted benzimidazoles, benzothiazoles and benzoxazoles |
| WO2011005295A1 (en) | 2009-06-24 | 2011-01-13 | Arena Pharmaceuticals, Inc. | Modulators of the sphingosine-1-phosphate (s1p) receptor useful for the treatment of disorders related thereto |
| EP2475664A2 (en) | 2009-09-11 | 2012-07-18 | Sunovion Pharmaceuticals Inc. | Histamine h3 inverse agonists and antagonists and methods of use thereof |
| JP5643332B2 (ja) | 2009-12-07 | 2014-12-17 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ピロロピリジンまたはベンゾイミダゾールコアを含有する複素環化合物 |
| WO2011109237A2 (en) | 2010-03-02 | 2011-09-09 | Emory University | Uses of noscapine and derivatives in subjects diagnosed with fap |
| US8654867B2 (en) | 2011-12-07 | 2014-02-18 | Texas Instruments Incorporated | Transformer power combiner with filter response |
| WO2013138565A1 (en) * | 2012-03-16 | 2013-09-19 | Vitae Pharmaceuticals, Inc. | Liver x receptor modulators |
| WO2013138568A1 (en) | 2012-03-16 | 2013-09-19 | Vitae Pharmaceuticals, Inc. | Liver x reception modulators |
-
2013
- 2013-03-14 WO PCT/US2013/031242 patent/WO2013138565A1/en not_active Ceased
- 2013-03-14 SG SG11201405328SA patent/SG11201405328SA/en unknown
- 2013-03-14 HR HRP20161196TT patent/HRP20161196T1/hr unknown
- 2013-03-14 ME MEP-2016-211A patent/ME02534B/me unknown
- 2013-03-14 AU AU2013232066A patent/AU2013232066B2/en not_active Ceased
- 2013-03-14 PT PT137121026T patent/PT2825541T/pt unknown
- 2013-03-14 MX MX2014011103A patent/MX354818B/es active IP Right Grant
- 2013-03-14 DK DK13712102.6T patent/DK2825541T3/en active
- 2013-03-14 NZ NZ629122A patent/NZ629122A/en not_active IP Right Cessation
- 2013-03-14 ES ES13712102.6T patent/ES2598653T3/es active Active
- 2013-03-14 LT LTEP13712102.6T patent/LT2825541T/lt unknown
- 2013-03-14 EP EP13712102.6A patent/EP2825541B1/en active Active
- 2013-03-14 IN IN7636DEN2014 patent/IN2014DN07636A/en unknown
- 2013-03-14 US US14/385,688 patent/US9006244B2/en active Active
- 2013-03-14 RS RS20160785A patent/RS55166B1/sr unknown
- 2013-03-14 SI SI201330303A patent/SI2825541T1/sl unknown
- 2013-03-14 CA CA2866218A patent/CA2866218C/en not_active Expired - Fee Related
- 2013-03-14 CN CN201380014354.5A patent/CN104203951B/zh not_active Expired - Fee Related
- 2013-03-14 PL PL13712102.6T patent/PL2825541T3/pl unknown
- 2013-03-14 EA EA201491609A patent/EA026907B1/ru unknown
- 2013-03-14 HU HUE13712102A patent/HUE029402T2/en unknown
- 2013-03-14 KR KR1020147028754A patent/KR102069912B1/ko not_active Expired - Fee Related
- 2013-03-14 JP JP2015500602A patent/JP6114814B2/ja not_active Expired - Fee Related
-
2014
- 2014-08-24 IL IL234265A patent/IL234265B/en active IP Right Grant
- 2014-08-27 ZA ZA201406326A patent/ZA201406326B/en unknown
- 2014-11-19 US US14/547,804 patent/US9006245B2/en active Active
-
2015
- 2015-03-13 US US14/657,179 patent/US9388190B2/en active Active
-
2016
- 2016-06-15 US US15/182,749 patent/US9814715B2/en active Active
- 2016-09-22 CY CY20161100948T patent/CY1118318T1/el unknown
- 2016-10-14 SM SM201600374T patent/SMT201600374B/it unknown
-
2017
- 2017-03-14 JP JP2017048432A patent/JP2017128588A/ja active Pending
-
2018
- 2018-09-14 JP JP2018172260A patent/JP2019023196A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ629122A (en) | Liver x receptor modulators | |
| NZ629189A (en) | Liver x receptor modulators | |
| LTPA2020504I1 (lt) | Pakeistieji pirazolo[1,5-a]pirimidino junginiai kaip Trk kinazės slopikliai | |
| NZ630721A (en) | Pyrazolo[1,5-a]pyrimidine-based compounds, compositions comprising them, and methods of their use | |
| NZ626394A (en) | Substituted annulated pyrimidines and triazines, and use thereof | |
| NZ629432A (en) | Heterocyclyl compounds as mek inhibitors | |
| EA201290147A1 (ru) | Пирроло[2,3-d]пиримидиновые соединения | |
| MX2013007148A (es) | 2-arilimidazo[1,2-b]piridazina, 2-fenilimidazo[1,2-a]pirimidina, y derivados de 2-fenilimidazo[1.2-a]pirazina. | |
| EA201390199A1 (ru) | 2-замещенные-8-алкил-7-оксо-7,8-дигидропиридо[2,3-d]пиримидин-6-карбонитрилы и их применение | |
| EA201170769A1 (ru) | Органические соединения | |
| NZ590777A (en) | PYRIMIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE FOR INHIBITING mTOR | |
| EA201170771A1 (ru) | Органические соединения | |
| PH12013502020A1 (en) | Pyrrolo [2,3-d] pyrimidine derivatives as inhibitors of tropomyosin-related kinases | |
| NZ703111A (en) | Novel 3,5-disubstitued-3h-imidazo[4,5-b]pyridine and 3,5- disubstitued -3h-[1,2,3]triazolo[4,5-b] pyridine compounds as modulators of protein kinases | |
| NZ627454A (en) | 2-amino, 6-phenyl substituted pyrido [2,3-d] pyrimidine derivatives useful as raf kinase inhibitors | |
| BR112012019511A2 (pt) | compostos de pirrolo [2,3-d] pirimidina como inibidores de jak. | |
| MX2013013294A (es) | Inhibidores de tirosina-cinasas. | |
| NZ630719A (en) | Imidazo [1, 2 - b] pyridazine - based compounds, compositions comprising them, and uses thereof | |
| AU2014270524A8 (en) | 2-phenylimidazo [1,2-a]pyrimidines as imaging agents | |
| MY167575A (en) | Heterocyclic compounds and use thereof as modulators of type iii receptor tyrosine kinases | |
| TN2018000087A1 (en) | New pyrrolo[2,3-d]pyrimidine derivatives as dual dyrk1/clk1 inhibitors | |
| TN2010000070A1 (en) | Fused bicyclic pyrimidines | |
| WO2009156951A3 (en) | 5,6,7,8-tetrahydro-imidazo[1,5-a]pyrazine compounds | |
| AU2017319080A1 (en) | Pyrazolo[1,5-a]pyrimidine compound | |
| PH12014500107A1 (en) | N- (6- ( (2r,3s) -3,4-dihydroxybutan-2-yloxy) -2- (4 - fluorobenzylthio) pyrimidin- 4 - yl) -3- methylazetidine- 1 - sulfonamide as chemokine receptor modulator |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 14 MAR 2018 BY CPA GLOBAL Effective date: 20170127 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 14 MAR 2019 BY CPA GLOBAL Effective date: 20180125 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 14 MAR 2020 BY COMPUTER PACKAGES INC Effective date: 20190219 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 14 MAR 2021 BY COMPUTER PACKAGES INC Effective date: 20200218 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 14 MAR 2022 BY COMPUTER PACKAGES INC Effective date: 20210306 |
|
| LAPS | Patent lapsed |